Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.64 |
| ▸ | KCNQ3 | O43525 | 16/20 | 0.51 |
| ▸ | KCNQ2 | O43526 | 16/20 | 0.51 |
| ▸ | KCNE1 | P15382 | 10/20 | 0.48 |
| ▸ | KCNQ1 | P51787 | 10/20 | 0.48 |
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1775532 | 0.80 | NPC1 (0.65) | RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL1779089 | 0.80 | RAB9A (0.59) | RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL1777253 | 0.79 | RAB9A (0.61) | RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL1400025 | 0.78 | NPC1 (0.57) | RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL1780371 | 0.76 | RAB9A (0.55) | RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL12508094 | 0.76 | RAB9A (0.55) | RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL1400157 | 0.76 | NPC1 (0.61) | RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL1777838 | 0.75 | RAB9A (0.58) | RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL1778349 | 0.74 | RAB9A (0.54) | RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL1400024 | 0.73 | NPC1 (0.64) | RAB9ANPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943638-B2 | Carboxamide compound and use of the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-05-17 | — | — | US | disclosed |
| US-7943638-B2 | Carboxamide compound and use of the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-05-17 | — | — | US | disclosed |
| US-7943638-B2 | Carboxamide compound and use of the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-05-17 | — | — | US | disclosed |
| EP-1915365-B1 | CARBOXAMIDE COMPOUND AND USE OF THE SAME | SUMITOMO CHEMICAL CO (JP) | 2011-03-02 | — | — | EP | disclosed |
| US-20090111852-A1 | Carboxamide Compound and Use of the Same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-04-30 | — | — | US | disclosed |
| US-20090111852-A1 | Carboxamide Compound and Use of the Same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-04-30 | — | — | US | disclosed |
| US-20090111852-A1 | Carboxamide Compound and Use of the Same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-04-30 | — | — | US | disclosed |
| EP-1915365-A2 | CARBOXAMIDE COMPOUND AND USE OF THE SAME | Sumitomo Chemical Company, Limited (JP) | 2008-04-30 | — | — | EP | disclosed |
| WO-2007007903-A2 | CARBOXAMIDE COMPOUND AND USE OF THE SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-01-18 | — | — | WO | disclosed |
| WO-2007007903-A2 | CARBOXAMIDE COMPOUND AND USE OF THE SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111852-A1 | Carboxamide Compound and Use of the Same | CBR3, H1-3, H1-0 | RAB9A 1566/4885NPC1 1962/4885KCNQ3 1118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.